Published in Hum Pathol on November 01, 2003
Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg (2008) 1.85
Can we agree to disagree? Hum Pathol (2003) 1.40
Follicular adenoma and carcinoma of the thyroid gland. Oncologist (2011) 1.21
How to combine ultrasound and cytological information in decision making about thyroid nodules. Eur Radiol (2009) 1.14
A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer (2007) 0.95
Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn (2006) 0.88
Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch (2009) 0.83
QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study. BMC Cancer (2009) 0.82
Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. BMC Med Genomics (2013) 0.81
Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg (2014) 0.81
[Molecular pathology of thyroid tumors]. Pathologe (2010) 0.80
Can CD10 be used as a diagnostic marker in thyroid pathology? Virchows Arch (2008) 0.79
NDRG1 protein overexpression in malignant thyroid neoplasms. Clinics (Sao Paulo) (2010) 0.77
Follicular Thyroid Carcinoma: How Have Histologic Diagnoses Changed in the Last Half-Century and What Are the Prognostic Implications? Thyroid (2015) 0.77
Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers. PLoS One (2009) 0.77
Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions. Adv Biomed Res (2014) 0.76
Molecular profiling of thyroid nodule fine-needle aspiration cytology. Nat Rev Endocrinol (2017) 0.75
The Intraoperative Immunohistochemical Staining of CD56 and CK19 Improves Surgical Decision for Thyroid Follicular Lesions. J Pathol Transl Med (2017) 0.75
The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms. Appl Immunohistochem Mol Morphol (2016) 0.75
When Is Thyroidectomy the Right Choice? Comparison between Fine-Needle Aspiration and Final Histology in a Single Institution Experience. Eur Thyroid J (2016) 0.75
European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. Eur Thyroid J (2017) 0.75
A communication strategy and brochure for relatives of patients dying in the ICU. N Engl J Med (2007) 10.13
Risk of post-traumatic stress symptoms in family members of intensive care unit patients. Am J Respir Crit Care Med (2005) 6.52
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA (2003) 4.84
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol (2002) 3.69
Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 study group. J Clin Oncol (2004) 3.64
Burnout syndrome in critical care nursing staff. Am J Respir Crit Care Med (2006) 3.62
Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA (2010) 3.50
Half the family members of intensive care unit patients do not want to share in the decision-making process: a study in 78 French intensive care units. Crit Care Med (2004) 3.31
The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med (2009) 3.30
Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol (2013) 3.14
DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J (2004) 2.85
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 2.81
The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med (2002) 2.79
Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis (2002) 2.71
Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med (2010) 2.62
Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. Crit Care Med (2008) 2.56
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood (2008) 2.55
Fumagillin treatment of intestinal microsporidiosis. N Engl J Med (2002) 2.52
Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med (2012) 2.45
Impact of a family information leaflet on effectiveness of information provided to family members of intensive care unit patients: a multicenter, prospective, randomized, controlled trial. Am J Respir Crit Care Med (2002) 2.44
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood (2013) 2.42
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol (2014) 2.40
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood (2007) 2.36
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol (2005) 2.35
Important questions asked by family members of intensive care unit patients. Crit Care Med (2011) 2.22
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood (2008) 2.21
Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol (2005) 2.16
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology (2011) 2.14
Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting. PLoS One (2010) 2.10
Prevalence and factors of intensive care unit conflicts: the conflicus study. Am J Respir Crit Care Med (2009) 2.08
Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med (2002) 2.07
The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med (2007) 2.05
Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med (2003) 2.01
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst (2012) 1.96
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging (2010) 1.87
Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med (2010) 1.77
Factors influencing inclusion of patients with malignancies in clinical trials. Cancer (2006) 1.76
Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med (2004) 1.72
Opinions about surrogate designation: a population survey in France. Crit Care Med (2003) 1.72
Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood (2010) 1.69
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol (2009) 1.67
Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med (2013) 1.67
Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution. Stat Med (2006) 1.66
Outcomes in critically ill cancer patients with septic shock of pulmonary origin. Shock (2013) 1.65
Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology (2015) 1.62
The prognosis of acute respiratory failure in critically ill cancer patients. Medicine (Baltimore) (2004) 1.62
Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol (2011) 1.62
Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab (2002) 1.59
Evaluating mortality in intensive care units: contribution of competing risks analyses. Crit Care (2006) 1.58
Noninvasive mechanical ventilation in patients having declined tracheal intubation. Intensive Care Med (2012) 1.56
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood (2006) 1.55
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging (2003) 1.53
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood (2009) 1.52
Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med (2003) 1.51
Hui and Walter's latent-class reference-free approach may be more useful in assessing agreement than diagnostic performance. J Clin Epidemiol (2005) 1.51
Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2015) 1.51
Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol (2007) 1.49
Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood (2003) 1.49
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol (2010) 1.48
Clinical outcome after laparoscopic adrenalectomy for primary hyperaldosteronism: the role of pathology. Surgery (2010) 1.48
Homeless Patients in the ICU: An Observational Propensity-Matched Cohort Study. Crit Care Med (2015) 1.46
Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol (2008) 1.46
Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study. Contemp Clin Trials (2010) 1.46
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol (2006) 1.46
Repeat measurement of cervical length after successful tocolysis. Obstet Gynecol (2004) 1.44
Primary hyperparathyroidism from parathyroid microadenoma: specific features and implications for a surgical strategy in the era of minimally invasive parathyroidectomy. J Am Coll Surg (2010) 1.42
Application of the continual reassessment method to dose-finding studies in regional anesthesia: an estimate of the ED95 dose for 0.5% bupivacaine for ultrasound-guided supraclavicular block. Anesthesiology (2013) 1.40
Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest (2009) 1.38
Anatomy of the epidemiological literature on the 2003 SARS outbreaks in Hong Kong and Toronto: a time-stratified review. PLoS Med (2010) 1.31
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol (2011) 1.30
Long-term outcome of iatrogenic gas embolism. Intensive Care Med (2010) 1.28
Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med (2011) 1.25
Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev (2012) 1.25
Clinically documented pleural effusions in medical ICU patients: how useful is routine thoracentesis? Chest (2002) 1.22
Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med (2003) 1.18
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol (2008) 1.16
Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol (2005) 1.14
Recent developments in adaptive designs for Phase I/II dose-finding studies. J Biopharm Stat (2007) 1.11
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene (2002) 1.10
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget (2010) 1.09
Sample size formula for proportional hazards modelling of competing risks. Stat Med (2004) 1.08
A thyroid nodule revealing a paraganglioma in a patient with a new germline mutation in the succinate dehydrogenase B gene. Eur J Endocrinol (2004) 1.07
Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood (2002) 1.07
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica (2011) 1.06
Practical methodology of meta-analysis of individual patient data using a survival outcome. Contemp Clin Trials (2007) 1.06
Improving estimates of event incidence over time in populations exposed to other events: application to three large databases. J Clin Epidemiol (2003) 1.06
p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast (2013) 1.05